- Days
- Hours
- Minutes
- Seconds
About This Event
As the field of oncology progresses, the evolution of multi-antigen specific therapies, especially within hematological malignancies, is accelerating. Promising approaches and therapeutic modalities like bispecific antibodies (bysp), dual CAR-Ts, and combination therapies are at the forefront of this development. Addressing the distinct challenges posed by safety and toxicity across diverse therapeutic modalities is imperative for their successful translation into clinical practice.
In this webinar, we'll explore the dynamic landscape of multispecific treatment strategies in hematological malignancies. Through this discussion, we aim to uncover their future implications, particularly in overcoming resistance mechanisms and enhancing safety profiles, thus illuminating the transformative potential of these strategies in the treatment of hematological cancers.
Our agenda of the webinar includes:
- Success of Bispecific T-cell engagers in Hematological Malignancies
- Therapeutic Potential and Significance of Bispecific T-cell engagers in Hematological Malignancies-
- Dynamic Evolving Landscape of multispecific treatment modalities
- Strategies to Optimize Efficacy and Safety Profiles of Current and Emerging Modalities
Join us as we explore each aspect, unveiling the intricacies and opportunities within the domain of multispecific therapies for hematological malignancies.
Register Now
Our Panel of Experts
Shivali Jasrotia
Shivali holds a doctoral degree in translational research with a focus on oncology. With over 4 years of experience in oncology consulting, she excels in strategic and evidence-based solutions, covering portfolio analysis, opportunity prioritization, market sizing, competitive intelligence, and product development.
Ankita Malik
Ankita is a Ph.D. in molecular biology. She has deep expertise in oncology business research and consulting, R&D strategy, and competitive and treatment landscapes for companies developing oncology assets.